Overview

4.5 out of 5 (4 Reviews)

Credits

1.00

Post Assessment Questions

7

Start Date

1 Sep 2023

Last Review Date

28 Feb 2024

Expiration Date

31 Aug 2026

Estimated Time To Finish

60 Minutes


 
Need Help?  If you have a system or content concerns, please contact support@statpearls.com

Activity Description

Lamivudine, a nucleoside reverse transcriptase inhibitor (NRTI), is a cornerstone in the therapeutic landscape for managing HIV-1 and hepatitis B infections. This comprehensive activity explores the diverse indications and contraindications for lamivudine across both conditions, elucidating its mechanism of action as a pivotal component in treating these disorders. Healthcare professionals will gain the necessary knowledge to navigate the nuances of lamivudine usage through a detailed examination of pharmacodynamics, pharmacokinetics, and relevant interactions. The program emphasizes the importance of vigilant monitoring to assess treatment responses and manage potential adverse events effectively, enabling the healthcare team to optimize patient care and outcomes in these infectious diseases.

In addition to its established uses, this activity discusses the broader therapeutic scope of lamivudine, including off-label applications where applicable, providing a comprehensive understanding of its clinical utility. By emphasizing the complexities of dosing and relevant interactions, the course prioritizes lamivudine's optimal administration and incorporation into individualized treatment regimens. Illuminating the imperative role of interprofessional collaboration in steering patients through effective monitoring strategies, the program strives to empower healthcare professionals with the necessary insights to navigate challenges in managing patients with HIV and hepatitis B infections. This initiative aims to improve clinical outcomes and enhance patient care by highlighting lamivudine's mechanism of action and adverse event profile.


UAN: JA4008338-0000-23-2597-H01-P

Target Audience

This activity has been designed to meet the educational needs of physicians, physician associates, nurses, pharmacists, and nurse practitioners.

Learning Objectives

At the conclusion of this activity, the learner will be better able to:

  • Identify the specific indications for lamivudine in managing HIV-1 and hepatitis B infections, understanding its role within antiretroviral therapy.

  • Screen patients to assess their suitability for lamivudine therapy, considering factors such as viral load, resistance patterns, and liver function tests.

  • Assess the patient's response to lamivudine therapy, monitor viral load, liver function, and potential adverse effects, and adjust treatment based on these assessments.

  • Implement communication with patients about the benefits, potential risks, and expected outcomes of lamivudine therapy, facilitating shared decision-making and promoting adherence.

Pharmacy Activity Type:
General Pharmacy Topic


Disclosures

StatPearls, LLC requires everyone who influences the content of an educational activity to disclose relevant financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflict(s) of interest have been mitigated. Hover over contributor names for financial disclosures. Others involved in planning this educational activity have no relevant financial relationships to disclose.

Commercial Support: This activity has received NO commercial support.

Continuing Education Accreditation Information

In support of improving patient care, StatPearls, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

 

Pharmacists: StatPearls, LLC designates this activity for a maximum of 1.00 ACPE credit(s). (UAN: JA4008338-0000-23-2597-H01-P ). Pharmacists should only claim credit commensurate with the extent of their participation in the activity.

Please consult your professional licensing board for information on the applicability and acceptance of continuing education credit for this activity.

Method of Participation and Credit

  1. Register for the activity.    
  2. Review the target audience, learning objectives, and disclosure information.
  3. Study the educational content of the enduring material.
  4. Choose the best answer to each activity test question. To receive credit and a certificate, you must pass the test questions with a minimum score of 100%.
  5. Complete the post-activity assessment survey.

If you have concerns regarding the CE/CME system, please contact support@statpearls.com.

Disclaimer

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Faculty may discuss investigational products or off-label uses of products regulated by the FDA. Readers should verify all information before employing any therapies described in this educational activity.

The information provided for this activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. The information presented does not necessarily reflect the views of StatPearls or any commercial supporters of educational activities on statpearls.com. StatPearls expressly disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through a participant's misunderstanding of the content.

Unapproved Uses of Drugs/Devices: In accordance with FDA requirements, the audience is advised that information presented in this continuing education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA-approved package insert for each drug/device for full prescribing/utilization information.

Cancellation Policy: Please see the cancellation policy. StatPearls, LLC reserves the right to cancel any course due to unforeseen circumstances.

 

 
 

Reviews

Goran Gailani O. on 3/11/2022

Dr.NIRMALA M. on 12/16/2022

Christine G. on 9/5/2023

sammy s. on 1/11/2024

Unlimited Pharmacist CE

Stay up to date on the latest medical knowledge with 6673 CE activities. In these online self-assessment activities, read our reference articles and test your knowledge with more than 7924.5 hours of CE.

Single Activity

Take this single activity

$29 1 activity

6 Month Unlimited Pharmacist CE

Access to all the Unlimited Pharmacist CE activities in all specialties.

$119 per half year per user

1 Year Unlimited Pharmacist CE

Access to all the Unlimited Pharmacist CE activities in all specialties.

$199 per 1 year per user